Summary of Use during Lactation

Limited experience with the use of ophthalmic dorzolamide indicate that it is unlikely to adversely affect the breastfed infant.[1] French guidelines recommend ophthalmic carbonic anhydrase inhibitor drops as a preferred therapy for glaucoma during breastfeeding.[2] To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A newborn infant was breastfed during maternal therapy with various combinations of ocular timolol, dipivifrin, dorzolamide, brimonidine and several doses of acetazolamide. Ultimately, the mother was treated with timolol gel-forming solution 0.5% and dorzolamide 2% drops. The drugs were given immediately following breastfeeding with punctal occlusion and no apnea or bradycardia was observed in the infant.[3]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Belkin A, Chen T, DeOliveria AR, et al. A practical guide to the pregnant and breastfeeding patient with glaucoma. Ophthalmol Glaucoma. 2020;3:79–89. [PubMed: 32672600]

2.

Blumen-Ohana E, Sellem E. J Fr Ophtalmol. 2020;43:63–6. [Pregnancy & glaucoma: SFO-SFG recommendations] [PubMed: 31813552]

3.

Johnson SM, Martinez M, Freedman S. Management of glaucoma in pregnancy and lactation. Surv Ophthalmol. 2001;45:449–54. [PubMed: 11274697]

Substance Name

Dorzolamide

CAS Registry Number

120279-96-1

Drug Class

Breast Feeding

Lactation

Antiglaucoma Agents

Carbonic Anhydrase Inhibitors